Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov 28:6:394.
doi: 10.7916/D81836S1. eCollection 2016.

History of Botulinum Toxin Treatment in Movement Disorders

Bahman Jabbari  1
Affiliations
Review

History of Botulinum Toxin Treatment in Movement Disorders

Bahman Jabbari. Tremor Other Hyperkinet Mov (N Y). .

Abstract

Background: The frontiers of clinical medicine constantly expand as a result of the innovative efforts of visionary researchers and keen observations of seasoned clinicians. In medicine, rarely has a therapeutic agent been found efficacious in the management of so many symptoms and in such a relatively short time as botulinum toxin. One of the most notable contributions of botulinum toxin therapy in clinical medicine is in the field of movement disorders.

Methods: The English literature was searched using the Yale search engine including but not limited to PubMed and Ovid. The search includes articles from January 1 1980 to March 1 2016.

Results: A total of 2055 articles were identified. Of these, 132 met the criteria for this review.

Discussion: This historical review highlights early and seminal contributions that have introduced the application of botulinum toxins in the field of movement disorders and provides evidence-based contributions that have established botulinum toxin as an effective treatment for abnormal movements.

Keywords: Movement disorders; abobotulinumtoxinA; botulinumtoxin; dystonia; incobotulinumtoxinA; onabotulinumtoxinA; rimabotulinum toxinB.

PubMed Disclaimer

Conflict of interest statement

Funding: None. Conflict of Interest: The author reports no conflict of interest. Ethics Statement: Not applicable for this category of article.

References

    1. Devriese P. On the discovery of Clostridium botulinum. J Hist Neurosci. 1999;8:43–50. doi: 10.1076/jhin.8.1.43.1774. - DOI - PubMed
    1. Drachman DB. Pharmacological denervation of skeletal muscle in chick embryos treated with botulinum toxin. Trans Am Neurol Assoc. 1965;90:241–242. - PubMed
    1. Pickett A. Pharmacological properties and factors that influence toxin action. Toxicon. 2009;54:683–689. doi: 10.1016/j.toxicon.2009.03.020. - DOI - PubMed
    1. Rossetto O, Megighian A, Scorzeto M, Montecucco C. Botulinum neurotoxins. Toxicon. 2013;67:31–36. doi: 10.1016/j.toxicon.2013.01.017. - DOI - PubMed
    1. Söllner T, Whiteheart SW, Brunner M, et al. SNAP receptors implicated in vesicle targeting and fusion. Nature. 1993;36:318–324. - PubMed

LinkOut - more resources